# Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma

> **NCT05170503** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 37 (estimated)

## Conditions studied

- Esophagogastric Junction Adenocarcinoma

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT05170503
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-29
- **Primary completion:** 2026-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05170503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05170503, "Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05170503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*